Petra Seibold1, Adam Webb2, Miguel E Aguado-Barrera3, David Azria4, Celine Bourgier4, Muriel Brengues5, Erik Briers6, Renée Bultijnck7, Patricia Calvo-Crespo8, Ana Carballo8, Ananya Choudhury9, Alessandro Cicchetti10, Johannes Claßen11, Elena Delmastro12, Alison M Dunning13, Rebecca M Elliott9, Laura Fachal13, Marie-Pierre Farcy-Jacquet14, Pietro Gabriele12, Elisabetta Garibaldi12, Antonio Gómez-Caamaño15, Sara Gutiérrez-Enríquez16, Daniel S Higginson17, Kerstie Johnson18, Ramón Lobato-Busto19, Meritxell Mollà20, Anusha Müller21, Debbie Payne22, Paula Peleteiro8, Giselle Post7, Tiziana Rancati10, Tim Rattay18, Victoria Reyes20, Barry S Rosenstein23, Dirk De Ruysscher24, Maria Carmen De Santis25, Jörg Schäfer26, Thomas Schnabel27, Elena Sperk28, R Paul Symonds18, Hilary Stobart29, Begoña Taboada-Valladares8, Christopher J Talbot18, Riccardo Valdagni30, Ana Vega31, Liv Veldeman32, Tim Ward33, Christian Weißenberger34, Catharine M L West9, Jenny Chang-Claude35. 1. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: p.seibold@dkfz-heidelberg.de. 2. Department of Genetics and Genome Biology, University of Leicester, UK. 3. Fundación Pública Galega de Medicina Xenómica, Grupo de Medicina Xenómica (USC), Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela, Spain. 4. Department of Radiation Oncology, Montpellier Cancer Institute, Université Montpellier, Inserm U1194, France. 5. Institut de Recherche en Cancérologie de Montpellier, Montpellier Cancer Institute, Inserm U1194, France. 6. Patient advocat, Hasselt, Belgium. 7. Department of Human Structure and Repair, Ghent University, Belgium. 8. Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain. 9. Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, UK. 10. Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 11. Klinik für Strahlentherapie, Radiologische Onkologie und Palliativmedizin, ViDia Christliche Kliniken Karlsruhe, Germany. 12. Department of Radiation Oncology, Candiolo Cancer Institute - FPO, IRCCS, TO, Italy. 13. Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Research Labs, UK. 14. Department of Radiation Oncology, CHU Nîmes, France. 15. Instituto de Investigación Sanitaria de Santiago de Compostela, Spain; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain. 16. Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. 17. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA. 18. Leicester Cancer Research Centre, University of Leicester, UK. 19. Department of Medical Physics, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain. 20. Radiation Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. 21. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 22. Centre for Integrated Genomic Medical Research (CIGMR), University of Manchester, UK. 23. Department of Radiation Oncology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA. 24. Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands; KU Leuven, Radiation Oncology, Leuven, Belgium. 25. Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 26. Strahlentherapie Speyer, Germany. 27. Klinik für Strahlentherapie und Radiologische Onkologie, Klinikum der Stadt Ludwigshafen gGmbH, Germany. 28. Department of Radiation Oncology, Universitätsklinikum Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. 29. Independent Cancer Patients' Voice, UK. 30. Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Haematology-Oncology, University of Milan, Italy. 31. Fundación Pública Galega de Medicina Xenómica, Grupo de Medicina Xenómica (USC), Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela, Spain; Biomedical Network on Rare Diseases (CIBERER), Spain. 32. Department of Human Structure and Repair, Ghent University, Belgium; Department of Radiation Oncology, Ghent University Hospital, Belgium. 33. Trustee Pelvic Radiation Disease Association, NCRI CTRad Consumer, UK. 34. Zentrum für Strahlentherapie Freiburg, Germany. 35. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany.
Abstract
PURPOSE: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data. METHODS: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated. RESULTS: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade ≥2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung). CONCLUSION: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers. PATIENT SUMMARY: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life. Not all patients are equally sensitive to radiation "damage" but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available. In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries. In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity.
PURPOSE: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data. METHODS: An international, prospective cohort study recruited cancerpatients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated. RESULTS: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancerpatients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade ≥2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung). CONCLUSION: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers. PATIENT SUMMARY: Up to half of cancerpatients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life. Not all patients are equally sensitive to radiation "damage" but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available. In the REQUITE study 4400 breast, prostate and lung cancerpatients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries. In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity.
Authors: Sarah L Kerns; Ashley Amidon Morlang; Sharon M Lee; Derick R Peterson; Brian Marples; Hong Zhang; Kevin Bylund; Doug Rosenzweig; William Hall; Kim De Ruyck; Barry S Rosenstein; Richard G Stock; Antonio Gómez-Caamaño; Ana Vega; Paloma Sosa-Fajardo; Begoña Taboada-Valladares; Miguel E Aguado-Barrera; Chris Parker; Liv Veldeman; Valérie Fonteyne; Renée Bultijnck; Christopher J Talbot; R Paul Symonds; Kerstie Johnson; Tim Rattay; Adam Webb; Maarten Lambrecht; Dirk de Ruysscher; Ben Vanneste; Ananya Choudhury; Rebecca M Elliott; Elena Sperk; Carsten Herskind; Marlon R Veldwijk; Tiziana Rancati; Barbara Avuzzi; Riccardo Valdagni; David Azria; Marie-Pierre Farcy Jacquet; Jenny Chang-Claude; Petra Seibold; Catharine West; Michelle Janelsins; Yuhchyau Chen; Edward Messing; Gary Morrow Journal: Radiother Oncol Date: 2022-01-22 Impact factor: 6.280
Authors: Jeffrey C Buchsbaum; Michael G Espey; Ceferino Obcemea; Jacek Capala; Mansoor Ahmed; Pataje G Prasanna; Bhadrasain Vikram; Julie A Hong; Beverly Teicher; Molykutty J Aryankalayil; Michelle A Bylicky; C Norman Coleman Journal: J Clin Oncol Date: 2022-03-04 Impact factor: 50.717
Authors: Tiziana Rancati; Laura Lozza; Lara Bellardita; Riccardo Ray Colciago; Sarah Frasca; Maria Carmen De Santis; Simona Gay; Federica Palorini; Eliana La Rocca; Riccardo Valdagni Journal: Radiol Med Date: 2021-07-15 Impact factor: 3.469
Authors: Lenka Koklesova; Alena Liskova; Marek Samec; Tawar Qaradakhi; Anthony Zulli; Karel Smejkal; Karol Kajo; Jana Jakubikova; Payam Behzadi; Martin Pec; Pavol Zubor; Kamil Biringer; Taeg Kyu Kwon; Dietrich Büsselberg; Gustavo R Sarria; Frank A Giordano; Olga Golubnitschaja; Peter Kubatka Journal: EPMA J Date: 2020-05-29 Impact factor: 6.543
Authors: Michela Carlotta Massi; Francesca Gasperoni; Francesca Ieva; Anna Maria Paganoni; Paolo Zunino; Andrea Manzoni; Nicola Rares Franco; Liv Veldeman; Piet Ost; Valérie Fonteyne; Christopher J Talbot; Tim Rattay; Adam Webb; Paul R Symonds; Kerstie Johnson; Maarten Lambrecht; Karin Haustermans; Gert De Meerleer; Dirk de Ruysscher; Ben Vanneste; Evert Van Limbergen; Ananya Choudhury; Rebecca M Elliott; Elena Sperk; Carsten Herskind; Marlon R Veldwijk; Barbara Avuzzi; Tommaso Giandini; Riccardo Valdagni; Alessandro Cicchetti; David Azria; Marie-Pierre Farcy Jacquet; Barry S Rosenstein; Richard G Stock; Kayla Collado; Ana Vega; Miguel Elías Aguado-Barrera; Patricia Calvo; Alison M Dunning; Laura Fachal; Sarah L Kerns; Debbie Payne; Jenny Chang-Claude; Petra Seibold; Catharine M L West; Tiziana Rancati Journal: Front Oncol Date: 2020-10-15 Impact factor: 6.244
Authors: Tim Rattay; Petra Seibold; Miguel E Aguado-Barrera; Manuel Altabas; David Azria; Gillian C Barnett; Renée Bultijnck; Jenny Chang-Claude; Ananya Choudhury; Charlotte E Coles; Alison M Dunning; Rebecca M Elliott; Marie-Pierre Farcy Jacquet; Sara Gutiérrez-Enríquez; Kerstie Johnson; Anusha Müller; Giselle Post; Tiziana Rancati; Victoria Reyes; Barry S Rosenstein; Dirk De Ruysscher; Maria C de Santis; Elena Sperk; Hilary Stobart; R Paul Symonds; Begoña Taboada-Valladares; Ana Vega; Liv Veldeman; Adam J Webb; Catharine M West; Riccardo Valdagni; Christopher J Talbot Journal: Front Oncol Date: 2020-10-30 Impact factor: 6.244
Authors: Katalin Lumniczky; Nathalie Impens; Gemma Armengol; Serge Candéias; Alexandros G Georgakilas; Sabine Hornhardt; Olga A Martin; Franz Rödel; Dörthe Schaue Journal: Environ Int Date: 2020-12-05 Impact factor: 9.621